Potassium-Competitive Acid Blockers (PCAB): Pharmacology Made Easy & Clinically Relevant
The Potassium-Competitive Acid Blockers (PCAB) are antacids used in conditions like H. pylori & GERD. While they are similar to PPIs, their value lies in understanding the differences between them. Don't memorize. Learn to understand pharmacology.
To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why with Dr. Busti pharmacology review, we break down the newest entrant to the antacid category—the potassium-competitive acid blocker (P-CAB), vonoprazan. You’ll see how P-CABs differ from H₂ blockers and PPIs, why their rapid onset, >24-hour acid suppression, and basal acid control make them a valuable option when PPIs fall short, and where they fit for GERD, erosive esophagitis, and H. pylori.
We connect mechanism to practice: relevant anatomy, parietal-cell signaling, PK/PD (onset, duration, metabolism), drug interactions (including pH-dependent meds and CYP pathways), adverse effects (mirroring PPI risks), monitoring, and concise patient counseling (including the chromogranin A caveat).
Chapter Table of Contents
00:00 Introduction to PCABs: The New Acid-Suppressing Drug Class
00:37 Indications & Clinical Role: GERD, Erosive Esophagitis, H. pylori Regimens
01:23 Onset of Action & Why Rapid Acid Suppression Matters
03:48 Mechanism of Action: Potassium-Competitive Inhibition of H+/K+ ATPase
05:12 Acid-Related Disorders: GERD, Ulcers, Barrett’s & Bleeding Risk
10:22 Deep Dive: Parietal Cell Structure, Luminal vs Basolateral Membrane
12:48 Proton Pump Function vs PCAB Binding Characteristics
16:17 Dosing Considerations: Once-Daily Regimens & Patient-Specific Factors
17:20 Gene-Level & Cellular Effects: Receptor Biology and Longevity of Acid Blockade
22:40 Pharmacokinetics: CYP450 Pathways, Onset, Half-Life & Drug Interactions
24:22 Adverse Effects: Pneumonia, C. diff, SBP Risk & Altered Gastric Flora
25:36 Risk Factors for Adverse Events: Hospitalization, Travel Exposure, Antibiotic Use
#PCAB #Vonoprazan #pharmacology #gipharmacology #medicaleducation
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Dive Deeper
Bonus Video (ad free)
To view this video, please enable marketing cookies.
Downloads
Dive Deeper
Bonus Video
Downloads
Related Topics
